Vibostolimab is a monoclonal antibody against T cell immune proteins and the ITIM domain.Vibostolimab has shown anti-tumor activity in in vitro trials and can be used to study non-small cell lung cancer (NSCLC) and melanoma.

Belrestotug (EOS-448), an antagonistic anti-TIGIT (VSIG9, VSTM3) antibody of the human immunoglobulin G1 kappa (hIgG1 kappa) class, exhibits antineoplastic activity [1].

Tiragolumab(MTIG-7192A) is a monoclonal antibody that targets T-cell immunoglobulin and the ITIM structural domain (TIGIT).Tiragolumab is often used in combination with the PD-L1 inhibitor, Atezolizumab, for the treatment of solid malignant tumors such as non-small cell lung cancer.

Ociperlimab, a humanized IgG1 anti-TIGIT antibody, exhibits high affinity for the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. It effectively inhibits the interaction between TIGIT and its ligands PVR or PVR-L2, and is utilized in cancer research [1] [2].